Alpha Anomeric SA (acquired by AlphaRose)
Alpha Anomeric develops a novel oligonucleotide chemistry platform for inherited genetic diseases.
RNA-Modulating TherapeuticsGenetic Diseases
Founded: 2018
About
Alpha Anomeric is using a novel, proprietary oligonucleotide chemistry platform for the design of a new class of RNA modulating oligonucleotides. These will be evaluated for the treatment of various inherited genetic diseases.
Products & Services
-
Use Cases & Case Studies
-
Partnerships & Collaborations
-
Awards & Recognition
-